Showing results for "Cellectis"
business
New York Aims to Jump-Start City's Drug Industry With Tower PactNew York has reached an agreement with one of the largest real estate developers in biotechnology to build more Manhattan laboratory space, in a bid to catch up with smaller cities attracting life-sciences companies.October 18, 2018
business
Bay State Biotech Report: Merck, Novartis, CellectisMerck KGaA is considering the sale of its consumer health operations, Novartis calls a doctor to push breakthrough drugs forward, and Cellectis plunges after the FDA suspends a cancer study. That’s all on the Bay State Biotech Report, where Bloomberg biotechnology reporter and Boston radio host Anne Mostue discusses the latest in biotech news from the Boston area and across the nation.September 5, 2017
technology
Cancer Breakthroughs Can Quickly Become Tomorrow's Also-RanThis week was historic in the fight against cancer. Novartis AG got approval for the first treatment in a revolutionary new class of drugs, shortly after Gilead Sciences Inc. spent $11.9 billion on a biotech company working in the field.September 1, 2017